Neutralizing antibodies in hepatitis C virus infection: A review of immunological and clinical characteristics

Mitchell Kaplan, Samer Gawrieh, Scott J. Cotler, Donald M. Jensen

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Hepatitis C infection induces cross-reactive neutralizing antibodies that, in some cases, prevent primary infection in animal models. Neutralizing antibodies target the HVR1 of the E2 glycoprotein, and a conserved region at the C-terminus of HVR1 determines cross-reactivity. The humoral immune response appears to be the driving force leading to variability in HVR1, resulting in emergence of escape mutants and persistence of HCV infection. Advances in understanding the humoral response to HCV could facilitate development of a vaccine for hepatitis C as well as an effective HCIG preparation containing cross-reactive neutralizing antibodies to HCV.

Original languageEnglish (US)
Pages (from-to)597-604
Number of pages8
JournalGastroenterology
Volume125
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Virus Diseases
Neutralizing Antibodies
Hepacivirus
Hepatitis C
Humoral Immunity
Cross Infection
Infection
Glycoproteins
Vaccines
Animal Models

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Neutralizing antibodies in hepatitis C virus infection : A review of immunological and clinical characteristics. / Kaplan, Mitchell; Gawrieh, Samer; Cotler, Scott J.; Jensen, Donald M.

In: Gastroenterology, Vol. 125, No. 2, 01.08.2003, p. 597-604.

Research output: Contribution to journalReview article

Kaplan, Mitchell ; Gawrieh, Samer ; Cotler, Scott J. ; Jensen, Donald M. / Neutralizing antibodies in hepatitis C virus infection : A review of immunological and clinical characteristics. In: Gastroenterology. 2003 ; Vol. 125, No. 2. pp. 597-604.
@article{ed68534c86564b3693fdd076b959529a,
title = "Neutralizing antibodies in hepatitis C virus infection: A review of immunological and clinical characteristics",
abstract = "Hepatitis C infection induces cross-reactive neutralizing antibodies that, in some cases, prevent primary infection in animal models. Neutralizing antibodies target the HVR1 of the E2 glycoprotein, and a conserved region at the C-terminus of HVR1 determines cross-reactivity. The humoral immune response appears to be the driving force leading to variability in HVR1, resulting in emergence of escape mutants and persistence of HCV infection. Advances in understanding the humoral response to HCV could facilitate development of a vaccine for hepatitis C as well as an effective HCIG preparation containing cross-reactive neutralizing antibodies to HCV.",
author = "Mitchell Kaplan and Samer Gawrieh and Cotler, {Scott J.} and Jensen, {Donald M.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S0016-5085(03)00882-5",
language = "English (US)",
volume = "125",
pages = "597--604",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Neutralizing antibodies in hepatitis C virus infection

T2 - A review of immunological and clinical characteristics

AU - Kaplan, Mitchell

AU - Gawrieh, Samer

AU - Cotler, Scott J.

AU - Jensen, Donald M.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Hepatitis C infection induces cross-reactive neutralizing antibodies that, in some cases, prevent primary infection in animal models. Neutralizing antibodies target the HVR1 of the E2 glycoprotein, and a conserved region at the C-terminus of HVR1 determines cross-reactivity. The humoral immune response appears to be the driving force leading to variability in HVR1, resulting in emergence of escape mutants and persistence of HCV infection. Advances in understanding the humoral response to HCV could facilitate development of a vaccine for hepatitis C as well as an effective HCIG preparation containing cross-reactive neutralizing antibodies to HCV.

AB - Hepatitis C infection induces cross-reactive neutralizing antibodies that, in some cases, prevent primary infection in animal models. Neutralizing antibodies target the HVR1 of the E2 glycoprotein, and a conserved region at the C-terminus of HVR1 determines cross-reactivity. The humoral immune response appears to be the driving force leading to variability in HVR1, resulting in emergence of escape mutants and persistence of HCV infection. Advances in understanding the humoral response to HCV could facilitate development of a vaccine for hepatitis C as well as an effective HCIG preparation containing cross-reactive neutralizing antibodies to HCV.

UR - http://www.scopus.com/inward/record.url?scp=0042165921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042165921&partnerID=8YFLogxK

U2 - 10.1016/S0016-5085(03)00882-5

DO - 10.1016/S0016-5085(03)00882-5

M3 - Review article

C2 - 12891562

AN - SCOPUS:0042165921

VL - 125

SP - 597

EP - 604

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 2

ER -